Immunogenetics

Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board

Retrieved on: 
Tuesday, September 13, 2022
ASX, Institut Gustave Roussy, Institute, Autoimmune disease, Australian Securities Exchange, Publication, University of Paris, Antibody, Acquisition, IMM, Immunotherapy, Â, Patient, Cancer, Technology, NASDAQ, Board, GLOBE, PD-1, Immunogenetics, Russell, APC, IGR, Pharmaceutical industry, Vaccine, Immunology, Immutep, LAG-3

Prof. Triebel will join the Immutep Board with immediate effect.

Key Points: 
  • Prof. Triebel will join the Immutep Board with immediate effect.
  • He founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer of Immutep following the Companys acquisition of Immutep S.A in December 2014.
  • Immutep Chair, Russell Howard said: It is a privilege to welcome Frdric to Immuteps Board.
  • I look forward to working as part of the Board to realise the value of this promising product candidate.

Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D

Retrieved on: 
Thursday, July 7, 2022
Research, Infectious Diseases, Neurology, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Thomas Jefferson University Hospital, Haematopoietic system, Cell, Department, Multiple sclerosis, Oncology, Science, Malignancy, Patient, Blood, Bio, Adult, Program, Pennsylvania State University, COVID-19, Bachelor of Science in Human Biology, Company, Anzac of the Year Award, Professor, Transplant, Thomas Jefferson University, Degenerative disease, Health care, BMT, Terminology, CSO, Toxic shock syndrome, Virology, CRS, Neurology, Lymphatic system, Immunogenetics, Cancer, Therapy, Hospital, Clinical trial, Leukemia & Lymphoma Society, Cytokine release syndrome, Virus, Inauguration, Plague, CTL, Infection, Leadership, Multimedia, Forward-looking statement, Pharmaceutical industry, Vaccine, Medicine, D, Research

as Chief Scientific Officer (CSO) and Global Head of Research and Development.

Key Points: 
  • as Chief Scientific Officer (CSO) and Global Head of Research and Development.
  • View the full release here: https://www.businesswire.com/news/home/20220707005531/en/
    Acclaimed oncologist and immunotherapy expert, Neal Flomenberg, M.D.
  • joins Tevogen Bio as Chief Scientific Officer and Global Head of R&D (Photo: Business Wire)
    Most recently, Dr. Flomenberg served as Professor and Chairman of the Department of Medical Oncology and Deputy Director of Sidney Kimmel Cancer Center of Thomas Jefferson University & Hospital.
  • At Jefferson, Dr. Flomenberg also served as Director of the Hematologic Malignancies, Blood and Marrow Transplantation (BMT) Program.

ASTCT Presents Distinguished Honors at the 2022 Tandem Meetings

Retrieved on: 
Wednesday, April 27, 2022
University of Illinois at Chicago College of Dentistry, University of Washington School of Medicine, Twitter, Fred Hutchinson Cancer Research Center, Research, New, Chicago, Hospital, Petersdorf, List of lifetime achievement awards, Education, Program, Immunogenetics, Review, Blood, BMT, Mike Reese, Division, Transplant, HLA, Physician, University, Time, Association, Medical device, Hematology

Effie Petersdorf, M.D., was honored with the 2022 ASTCT Lifetime Achievement Award.

Key Points: 
  • Effie Petersdorf, M.D., was honored with the 2022 ASTCT Lifetime Achievement Award.
  • The 2022 ASTCT Public Service Award was presented to Damiano Rondelli, M.D.
  • The ASTCT Board of Directors recognized James W. Young, M.D., with the 2022 ASTCT Special Recognition for his outstanding contributions to the New Investigator Awards program.
  • For more information about ASTCT, visit www.astct.org and follow ASTCT on Twitter @ASTCT .

Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher

Retrieved on: 
Monday, March 21, 2022
Private Securities Litigation Reform Act, Risk, Therapy, National Kidney Foundation, Plasma, PTLD, Degenerative disease, Research, Medicine, B-cell activating factor, FASN, GLOBE, Immunogenetics, University, Security (finance), Nephrology, National, Immunosuppression, FAST, Pediatrics, Immunoglobulin A, BKV, BK virus, International Society, U.S. Securities and Exchange Commission, Medicare, Virus, Patent, Histocompatibility, Pharmacokinetics, BK, Standard of care, B cell, Patient, Post-transplant lymphoproliferative disorder, Life, Cedars-Sinai Medical Center, Pfizer, IVIG, IgA nephropathy, Viral load, Cancer, Polyomaviridae, Lupus nephritis, Cohort, Safety, PRISM, COVID-19, Infection, Autoantibody, KOL, Vera, Dentistry, Pharmaceutical industry, Transplant

BRISBANE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader (KOL) webinar discussing BK Virus (BKV) featuring world-renowned transplant nephrologist and pioneering kidney transplant researcher, Stanley C. Jordan, M.D., FASN, FAST. As part of the webinar, management will provide an overview of Vera’s lead asset in the treatment of BKV, MAU868, a first-in-class monoclonal antibody to treat BKV infections.

Key Points: 
  • BK Virus is a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant.
  • MAU868 is currently undergoing a randomized, double-blind, placebo-controlled Phase 2 clinical trial to assess the safety, pharmacokinetics, and efficacy for the treatment of BKV in kidney transplant patients.
  • In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful.
  • Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant.

Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors

Retrieved on: 
Monday, February 28, 2022
GLOBE, Sheffield Hallam University, MD Anderson Cancer Center, Risk, Internal medicine, Board of directors, Partnership, Board, SEC, GlaxoSmithKline, Oncology, Education, Security (finance), Public health, NASDAQ, MPH, Novartis, Annual report, University, COVID-19, Hematology, Drug development, Private Securities Litigation Reform Act, Jeff, Business, Oklahoma Office of the Chief Medical Examiner, U.S. Securities and Exchange Commission, Bristol Myers Squibb, Fisher College of Business, Lymphoma, Precision medicine, Michigan Medicine, McGill University Faculty of Medicine, Lymphoid leukemia, Cancer, The Washington Campus Board of Directors, MBA, Patient, CGEM, Doctor of Philosophy, Research, Annie Martin (artist), Pharmaceutical industry, Management, Immunogenetics, Medicine, Director

The appointments of Dr. Jeff Jones as Chief Medical Officer and of Dr. Annie Martin to our Board of Directors expands our expertise within the oncology space and brings diverse perspectives to our leadership team, said Nadim Ahmed, Chief Executive Officer of Cullinan Oncology.

Key Points: 
  • The appointments of Dr. Jeff Jones as Chief Medical Officer and of Dr. Annie Martin to our Board of Directors expands our expertise within the oncology space and brings diverse perspectives to our leadership team, said Nadim Ahmed, Chief Executive Officer of Cullinan Oncology.
  • Dr. Joness successful academic tenure and deep expertise in oncology drug development will be vital to our mission to create new standards-of-care for patients with cancer.
  • I am thrilled to welcome Dr. Anne-Marie Martin to the Cullinan Oncology Board of Directors, where she will bring her experience and vision for oncology product development, said Tony Rosenberg, Chairman of the Board of Directors of Cullinan Oncology.
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.